Aspirin chemoprevention of gastrointestinal cancer in the next decade: A review of the evidence

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 10, 2010, Pages 407-412

  Jankowska, Helena ^a   Hooper, Patricia ^b   Jankowski, Janusz A ^b,c,d  

^a Richard Hill School   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aspirin; Barrett's esophagus; Chemoprevention; Esophageal adenocarcinoma

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FOLIC ACID; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; STARCH;

ADENOCARCINOMA; ALLERGIC REACTION; BARRETT ESOPHAGUS; BRAIN HEMORRHAGE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG COST; DRUG TARGETING; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FAMILIAL POLYPOSIS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC);

EID: 78649616178     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.981     Document Type: Review

References (38)

1. Falk GW, Jankowski J. Chemoprevention and Barrett's esophagus: decisions, decisions. Am J Gastroenterol. 2008;103:2443-2445.
2. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett's oesophagus in the general population. Gut. 2005;54:1062-1066.
3. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918-922.
4. Jankowski J, Barr H, Wang K, Delaney B. The management of Barrett's oesophagus. Brit Med J. In press.
5. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology. 2002;122:588-590.
6. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion. 2007;76:51-67.
7. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006;3:101-111.
8. Beral V, Peto R. UK cancer survival statistics. BMJ. 2010;341: c4112.
9. Jankowski JA, Odze RD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol. 2009;104:1093-1096.
10. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-507.
11. Grau MV, Sandler RS, McKeown-Eyssen G, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267-276.
12. Cook NR, Lee IM, Gaziano JM. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47-55.
13. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer. 2007;121:2753-2760.
14. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med. 1999;340:825-831.
15. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust. 2004;180:387-391.
16. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009;7:1299-1304.
17. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal antiinflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6:945-952.
18. Heath EI, Canto MI, Paintadosi S. Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial. J Natl Cancer Inst. 2007;99:545-557.
19. Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiol Biomarkers Prev. 2008;17:1858-1861.
20. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97-102.
21. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-anafysis. G astroenterology 2003;124:47-56.
22. Anderson LA, Watson RGP, Murphy SJ. Risk Factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585-1594.
23. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and the incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220-1224.
24. González-Pérez A, García Rodríguez LA, López-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28.
25. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006;17:871-888.
26. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890. (Pubitemid 36297996)
27. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;6; 348:891-899.
28. Bum J, Bishop DT, Mecklin JP, et al; CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359; 2567-2578.
29. Das D, Chilton AP, Jankowski JA. Chemoprevention of esophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161-168.
30. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology. 2002;122:588-590.
31. Hur C, Nishioka G, Gazelle GS Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst. 2004;96:316-325.
32. Hur C, Broughton DE, Ozanne E, et al. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2008;103:2432-2442.
33. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther. 2008;27:316-320.
34. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280:1930-1935.
35. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.
36. Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers Gut. 1996;38:646-648.
37. Dunn LJ, Jankowski J. Chemoprevention of gastrointestinal cancer. Br J Surg. 2008;95:674-676.
38. Benamouzig R, Uzzan B, Martin A, et al; APACC Study Group. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut. 2010;59:622-629.